In pandemic flu preparation, a lot of focus is placed on protecting against the specific viral strain. Yet analysis of the 1918 pandemic shows secondary bacterial pneumonia directly caused many of the deaths. This brings Pfizer's Prevnar 13 into play, and the Big Pharma is talking up its role.
The agenda for the mammalian synthetic biology workshop held at the Massachusetts Institute of Technology last weekend demonstrates that renewed interest in vaccines has opened up new therapeutic targets, which in turn has driven new approaches to manufacturing. And the threats of pandemic flu and bioterrorism have acted as an extra innovation driver.
The arms race analogy for vaccines is rarely more apt than during a pandemic flu outbreak. Last week the U.S. touted a new, more streamlined approach to vaccine development. This week the virus raised the stakes with a surge of new cases that suggest it is adapting to human hosts.
Where is this year's flu outbreak? In the wake of the H1N1 drama of a couple of years back, the virus seems to be laying low in the U.S. this season. But don't let your guard down: Flu...
The swine flu virus will be with us indefinitely, but the World Health Organization says that the H1N1 pandemic it triggered is over. For the vaccine industry, the pandemic presented an opportunity
Rockville, MD-based Emergent BioSolutions has reached halfway around the world to join hands with a new partner to quickly develop a broad spectrum pandemic vaccine against multiple H5 strains.
The H1N1 flu pandemic is as severe as influenza pandemics in 1957 and 1968 and remains a threat to healthy young adults, John Mackenzie, the Australian who heads the World Health Organization's
Eight months after declaring the world's first pandemic in more than four decades, the World Health Organization says it will once again summon its experts to determine if the worst of the outbreak
First there wasn't enough swine flu vaccine, then there was plenty, and now it turns out that many countries may have too much. Out in Vancouver, Canadian health officials say that the initial clamor
In a fresh sign that everything pandemic-related gets swiftly shoved into the biotech spotlight these days, shares of Medicago have been buoyed by its announcement that Canadian regulators have